Skip to content
Resources > Reports

AI in Drug Development 2026: From Experimentation to Execution

By Sara Mallatt, Director of Healthcare Research and Sean Carmichael

AI has advanced from pilot programs into real biopharma workflows. But has it lived up to the hype? Drawing from an expert call with Dr. Paul Agapow, former director of data science at GSK, this report dissects whether AI is on track to make drug development faster, cheaper, and more successful. Learn how AI is reshaping drug development in real time, turning AI execution into a key competitive differentiator.

About the Authors
  • Sara Mallatt

    Sara Mallatt, Director of Healthcare Research

    Sara has more than 18 years of experience generating sell-side research content across a variety of industries. Prior to joining AlphaSense, Sara held leadership positions at OTR Global, a leading channel research firm, most recently as Director of Healthcare Research. Sara holds a bachelor’s degree in journalism and a master’s in industrial engineering. She works from her home in Missoula, Montana.
  • Sean Carmichael

    Sean Carmichael

    Sean is a Business & Finance Editor at AlphaSense, specializing in sector-specific content production. Previously, he spent nearly a decade in various roles across financial services, where he was responsible for equity research and content generation geared toward institutional investors.

Explore more

Top AI Use Cases for Venture Capital Firms

In this report, discover how venture capital teams are leveraging AI for decision-grade intelligence that distills signal from noise in a crowded environment.
A blue graphic titled "Top AI Use Cases for Venture Capital Firms" featuring an upward trending arrow, a stack of money, and a globe.

Top AI Use Cases for Law Firms

As generative AI compresses traditional billable hours and reshapes client expectations, elite law firms are fundamentally changing how they operate. Discover the top use cases that are transforming how elite law firms are winning mandates and driving business development in the AI era.
Top AI Use Cases for Law Firms title next to a light blue gavel and sound block on a grid.

The 2026 State of AI for Business and Finance

Among AI-engaged leaders and decision-makers, adoption is close to universal this year, and the daily payoff is real. Accuracy has become the No. 1 feature buyers want in an AI tool — ahead of privacy, output quality, and speed.
The 2026 State of AI for Business and Finance, From Adoption to Accountability.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.